BriaCell Therapeutics (TSE:BCT) has released an update.
BriaCell Therapeutics has reported significant advancements in treating advanced metastatic breast cancer with its novel immunotherapy, Bria-IMT™, evidenced by a doubling in median progression-free survival to 4.1 months for ADC-resistant patients and an 83% intracranial objective response rate at the ASCO 2024 Annual Meeting. The Phase 2 study results show a 55% clinical benefit rate across various patient groups, suggesting a potential game-changing therapy for those with limited treatment options.
For further insights into TSE:BCT stock, check out TipRanks’ Stock Analysis page.
